Imatinib
Drug Details
- Description
- Imatinib is a tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by inhibiting the BCR-ABL tyrosine kinase, which is produced by a specific chromosomal abnormality in these cancers. This inhibition blocks the proliferation of cancer cells and induces apoptosis.
- Alternative Names
- Imatinib: Brand name - Gleevec; Chemical name - Imatinib mesylate.
- Key Genes
- The key genes associated with Imatinib are ABL1, BCR, KIT, PDGFRA, and PDGFRB.
- Drug Use
- Imatinib is used to treat certain types of cancer, primarily chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report